医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Factory CRO and Boston Biomedical Associates Announce Merger

2019年01月07日 PM08:00
このエントリーをはてなブックマークに追加


 

BILTHOVEN, Netherlands & MARLBOROUGH, Mass.

Factory-CRO Group, a leading global contract research organization (CRO) focused on medical devices and in vitro diagnostics (IVDs), and Boston Biomedical Associates (BBA) a premier full-service Medical Device/Biotechnology CRO and Consultancy based in the United States announce that they have merged the organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190107005358/en/

The merger further advances the shared strategic vision to become the leading Global Medical Device and Medical Technology focused CRO. Following the recent acquisitions of MileStone Research Organization, Five Corners, and Clinical Device Group the Factory-CRO Group now has specialized operations and expertise in the United States, Australia/New Zealand, and Europe. This global expansion coupled with the diverse medical therapeutic expertise provides a means to efficiently service clients.

“BBA is excited to join Factory-CRO’s worldwide group as it will allow us to expand our comprehensive service offering to our clients,” said Lauren Baker, PhD, President and CEO of BBA. “The alignment of Factory-CRO and BBA’s core values and approach to engagements combined with our collective therapeutic competencies ensures that our clients now have improved access to our global clinical trial execution resources, and our regulatory and medical expertise.” Dr. Baker then added, “We are able to fully support our clients as their needs evolve and they strive to help patients globally.”

“We are honored to have the BBA team join the Factory-CRO Group,” said Dirk Meijer, MD, MSc,PhD, Factory-CRO CEO. “BBA’s ability to provide CRO/Consultative service in North America was a missing link in our global offerings.” Dr. Meijer then added, “Our clients have consistently asked us to expand our offerings in North America. This merger allows us to provide our specialized expertise and a continued commitment to the highest level of customized service to a larger audience. Now we are the only Medical Device and Medical Technology CRO that offers services in United States, Europe, Australia and New Zealand. We operate from our own offices located within each region housed with employees that have refined expertise to meet our unique client needs.”

About Factory-CRO Group:
Factory-CRO Group is a leading, full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics and device-drug combination products internationally. Founded in 1992, the business offers a full suite of trial management services to its global client base across a broad range of therapeutic areas, including orthopedic, cardiovascular, dermatology and aesthetics. Current members of Factory-CRO Group are: BBA, Five Corners CRO, Milestone Research group and Factory-CRO.

For more information about Factory-CRO, visit their website, www.factory-cro.com or contact Joris Bannenberg, MD, PhD, Factory-CRO’s CMO:

Joris Bannenberg, MD, PhD
CMO
j.bannenberg@factory-cro.com
+31 30 229 2727 (x108)

About Boston Biomedical Associates:
Boston Biomedical Associates (BBA) is a premier full-service Medical Device/Biotechnology CRO and Consultancy firm. Founded in 2000, by Lauren Baker, Ph.D., this leading CRO has earned a reputation for its comprehensive approach to clinical trial execution services to its global client base across a broad range of therapeutic areas, including orthopedic, cardiovascular, endocrine and neurologic disorders.

For more information about BBA, visit their website, www.bbacro.com or contact Mack Rubley, PhD, BBA’s Vice President of Business Development and Marketing:

Mack D. Rubley, PhD
VP, Business Development and Marketing
702-808-3494
mrubley@bbacro.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005358/en/

CONTACT

Joris Bannenberg, MD, PhD
CMO
j.bannenberg@factory-cro.com
+31
30 229 2727 (x108)

Mack D. Rubley, PhD
VP, Business Development and Marketing
702-808-3494
mrubley@bbacro.com

同じカテゴリーの記事 

  • Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
  • ReNAgade Therapeutics宣布在ASGCT第27届年会上发表演讲
  • ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表
  • BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
  • The 2024 Japan Prize Award Ceremony Is Held with Their Majesties the Emperor and Empress of Japan in Attendance